Aldeyra Therapeutics (ALDX) Financials

Aldeyra Therapeutics (NASDAQ: ALDX) remains a pre-revenue biotech story with a balance sheet that still offers meaningful runway, but the latest quarter shows the company continues to burn cash at a significant rate while operating losses persist. Over the last four years, the broad trend is clear: revenue has stayed at zero, losses have generally been large and recurring, and cash has steadily declined from very high levels in 2023 to a much lower but still solid position today.

• Cash and equivalents were $65.0 million at the end of Q1 2026, giving ALDX a buffer to keep funding operations.
• The company still has no long-term debt on the Q1 2026 balance sheet, which reduces balance-sheet risk.
• Q1 2026 other income was positive, with net other income of $94.3 thousand, helped by interest and investment income.
• Aldeyra has shown it can generate sizable investment income in prior periods, helping partially offset operating losses.
• Q1 2026 current assets of $66.3 million exceeded current liabilities of $24.3 million, indicating near-term liquidity coverage remains intact.
• Q1 2026 deferred revenue was $6.0 million, which is a modest source of liability but also suggests some customer/partner-related upfront cash has been received.
• Share count has been relatively stable recently, with Q1 2026 basic weighted average shares at about 60.3 million.
• Q1 2026 revenue remained $0, so the business is still fully dependent on financing and cash reserves.
• Q1 2026 net loss was $3.5 million, and operating expenses totaled $3.5 million, keeping the company unprofitable.
• Operating cash burn was still heavy at $(5.1) million in Q1 2026, which is the main risk for investors.

Looking across the last four years, Aldeyra’s operating performance has been consistently loss-making. Quarterly net losses in 2024 and 2025 were often much larger than in Q1 2026, commonly ranging from roughly $4.8 million to $16.8 million. That suggests expenses have been moderated recently, but the company is still not close to break-even.

The cash flow trend is especially important for retail investors. In 2024, Aldeyra was using cash aggressively, including several quarters with operating cash outflows near or above $10 million. In 2025 and into Q1 2026, operating burn remained negative, though the company occasionally boosted cash through investment maturities and sales. That helped offset losses, but it is not a durable operating solution.

The balance sheet has weakened over time. Cash and short-term investments peaked above $140 million combined in early 2024, then declined significantly through 2025 before stabilizing at a lower level in Q1 2026. At the same time, liabilities have stayed manageable, and the absence of long-term debt is a positive. Still, without product revenue, the company’s future depends heavily on clinical progress, financing access, or a partnership/approval event.

Bottom line: ALDX has a relatively clean balance sheet and enough cash for now, but the company is still a cash-burning, pre-revenue biotech with no top-line support. Investors should focus on the pace of cash burn, any clinical/regulatory catalysts, and whether management can extend runway without excessive dilution.